Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event, which runs from November 11-13, 2024. Dr. Cohen's fireside chat is scheduled for November 12, 2024, at 10:00 a.m. ET, and will be available via webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha annunciato la sua partecipazione alla prossima Conferenza sull'Innovazione Sanitaria di Guggenheim Securities a Boston, MA. Il CEO dell'azienda, Yuval Cohen, Ph.D., parteciperà a una conversazione informale e condurrà incontri one-to-one con gli investitori durante l'evento, che si terrà dal 11 al 13 novembre 2024. La conversazione di Dr. Cohen è programmata per il 12 novembre 2024, alle 10:00 ET, e sarà disponibile tramite webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) ha anunciado su participación en la próxima Conferencia de Innovación Sanitaria de Guggenheim Securities en Boston, MA. El CEO de la empresa, Yuval Cohen, Ph.D., participará en una charla informal y llevará a cabo reuniones individuales con inversores durante el evento, que se realizará del 11 al 13 de noviembre de 2024. La charla de Dr. Cohen está programada para el 12 de noviembre de 2024, a las 10:00 a.m. ET, y estará disponible a través de un webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP)는 매사추세츠주 보스턴에서 열리는 구겐하임 증권 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Yuval Cohen 박사님은 이벤트 기간 동안 화로챗에 참여하고 투자자들과 일대일 미팅을 진행할 예정입니다. 이 행사는 2024년 11월 11일부터 13일까지 열리며, Cohen 박사의 화로챗은 2024년 11월 12일 오전 10시(ET)에 예정되어 있으며 웹캐스트로 시청할 수 있습니다.
Corbus Pharmaceuticals (NASDAQ: CRBP) a annoncé sa participation à la prochaine Conférence sur l'Innovation en Santé de Guggenheim Securities à Boston, MA. Le PDG de l'entreprise, Yuval Cohen, Ph.D., participera à une discussion informelle et mènera des réunions individuelles avec des investisseurs durant l'événement qui se déroulera du 11 au 13 novembre 2024. La discussion de Dr. Cohen est prévue pour le 12 novembre 2024 à 10h00 ET et sera disponible en webcast.
Corbus Pharmaceuticals (NASDAQ: CRBP) hat seine Teilnahme an der bevorstehenden Guggenheim Securities Healthcare Innovation Conference in Boston, MA, angekündigt. Der CEO des Unternehmens, Yuval Cohen, Ph.D., wird an einem informellen Gespräch teilnehmen und individuelle Investorenmeetings während der Veranstaltung abhalten, die vom 11. bis 13. November 2024 stattfindet. Dr. Cohens informelles Gespräch ist für den 12. November 2024 um 10:00 Uhr ET geplant und wird über einen Webcast verfügbar sein.
- None.
- None.
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.
Guggenheim Securities Healthcare Innovation Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 12, 2024
Time: 10:00 a.m. ET
Webcast: Click here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When is Corbus Pharmaceuticals (CRBP) presenting at the Guggenheim Healthcare Conference 2024?
What type of presentation will CRBP give at the Guggenheim Healthcare Conference?
Where is the 2024 Guggenheim Securities Healthcare Innovation Conference being held?